Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
Recent Articles By The Author
Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
Sarepta Shares Still Have Upside
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
A New Reason to be Bullish About Sarepta Therapeutics
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
Idenix Pharma: Guilty By Association
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
Bull Case on Peregrine Pharma Shouldn't Be Dismissed
Believers in Peregrine's lung cancer drug bavituximab state their case.
Peregrine Pharma: Not Good Enough to Own, Too Risky to Short
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
More Reasons to Invest in Sarepta With Caution
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
Sarepta's Risks Shouldn't Be Ignored
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
In These Turbulent Times, Reach for Merck
The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.